Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials

By sjmartinez • March 6, 2025

Armstrong AW, Lebwohl M, Warren RB, Sofen H, Morita A, Paul C, Papp KA, Colombo MJ, Scotto J, Vaile J, Zhuo J, Vritzali E, Berger V, Schroeder G, Banerjee S, Thaçi D, Strober B. Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trials. J Eur Acad Dermatol Venereol. 2025 Mar 6. doi: 10.1111/jdv.20553. Epub ahead of print. PMID: 40045918.

Tags: Dermatology, Olive View DoM, Publications

A Response to: “Letter to the Editor Regarding ‘Anchored Matching-Adjusted Indirect Comparison of the Long-Term Maintenance of Efficacy of Tralokinumab and Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis'”

Augustin M, Armstrong AW, Issa NT, Petersen AS, von Eyben R, Festini T, Torres T. A Response to: "Letter to the Editor Regarding 'Anchored Matching-Adjusted[...]

Long-term disability outcomes in Hansen’s disease: A 20-year comparative study of Lepromatous vs. Tuberculoid Leprosy

Ma EJ, Adler BL, Armstrong AW, Ochoa MT. Long-term disability outcomes in Hansen's disease: A 20-year comparative study of Lepromatous vs. Tuberculoid Leprosy. PLoS Negl[...]

Impact of Online vs In-Person Management of Atopic Dermatitis on Quality of Life and Access to Care: A Randomized Controlled Trial

Armstrong AW, Roberts AM, Kostandy G, Choudhury F, Yee D, Luu M, Jones ME, Alizadeh ER, Cotliar J, Chren MM, Gelfand JM, Cockburn M, Doctor[...]